Process for preparing a composition comprising a high concentration of one or more avermectins
A process is described for preparing a composition in the form of an emulsion that includes a high concentration of one or more avermectins. This process can include partitioning the avermectin between an active phase, including at least one glycol, and an oily phase of the emulsion. A composition thus obtained, is also described that can be used in the treatment of dermatological disorders such as rosacea.
1. A process of manufacturing a composition in the form of an emulsion comprising at least one avermectin, the process comprising, successively:
(a) emulsifying an oily phase comprising from 0.05% to 3% by weight of the at least one avermectin, relative to the total weight of the composition with an aqueous phase at a temperature from 60° C. to 75° C. in order to obtain an emulsion;
(b) cooling the emulsion to a temperature from 48° C. to 55° C.;
(c) adding to the emulsion an active phase comprising 0.05% to 3% by weight of at least one avermectin, relative to the total weight of the composition, wherein the at least one avermectin is dissolved in a medium comprising at least one glycol; and
(d) cooling the emulsion to a temperature from 50° C. to 30° C.;
wherein the composition comprises 2% to 6% by weight of the at least one avermectin relative to the total weight of the composition.
2. The process according to claim 1 , wherein (d) comprises cooling the emulsion at a cooling rate of from 0.5° C. to 1.5° C./5 min.
3. The process according to claim 1 , wherein (d) comprises cooling the emulsion to a temperature selected from 42° C. to 47° C., and maintaining the temperature for 10 to 20 minutes; and further cooling the emulsion to a temperature from 30° C. to 40° C.
4. The process according to claim 1 , wherein the at least one avermectin is selected from the group consisting of ivermectin and optical isomers thereof.
5. The process according to claim 1 , wherein the at least one avermectin in the oily phase is in an amount from 2% to 3% by weight, relative to the total weight of the composition.
6. The process according to claim 2 , wherein the cooling rate is from 0.8° C. to 1.5° C./5 min.
7. The process according to claim 2 , wherein the cooling rate is 1° C./5 min.
8. The process according to claim 3 , wherein the selected temperature is maintained for 15 minutes.
9. The process according to claim 1 , wherein the at least one avermectin remains fully solubilized in the composition during manufacturing and for at least 1 month after manufacturing.
10. The process according to claim 1 , wherein the at least one avermectin remains fully solubilized in the composition during manufacturing and for at least 2 months post-manufacture.
11. The process according to claim 1 , wherein the at least one avermectin remains fully solubilized in the composition during manufacturing and for at least 3 months post-manufacture.
12. The process according to claim 1 , wherein the at least one avermectin remains fully solubilized in the composition at temperatures between 5° C. to 40° C.
13. The process according to claim 1 , wherein the glycol occurs in an amount between 0.5% to 15% by weight, relative to the total weight of the composition.
14. The process according to claim 13 , wherein the glycol is 2% by weight, relative to the total weight of the composition.
15. The process according to claim 1 , wherein the active phase represents between 1% to 18% of the total weight of the composition.
16. The process according to claim 1 , wherein the active phase comprises an alcohol.
17. The process according to claim 16 , wherein the glycol and the alcohol occur in a weight ratio between 1:4 to 4:1.